Royal Bank of Canada
PRME icon

Royal Bank of Canada’s Prime Medicine PRME Stock Holding History

Royal Bank of Canada’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32K Buy
9,254
+4,365
+89% +$16.6K ﹤0.01% 5694
2025
Q4 		$17K Buy
4,889
+3,046
+165% +$13.5K ﹤0.01% 6149
2025
Q3 		$11K Sell
1,843
-3,302
-64% -$13.4K ﹤0.01% 6457
2025
Q2 		$13K Buy
5,145
+3,505
+214% +$5.4K ﹤0.01% 6413
2025
Q1 		$3K Buy
1,640
+478
+41% +$1.22K ﹤0.01% 6513
2024
Q4 		$3K Sell
1,162
-9,523
-89% -$33.4K ﹤0.01% 6662
2024
Q3 		$41K Buy
10,685
+4,547
+74% +$21.1K ﹤0.01% 5799
2024
Q2 		$31K Buy
6,138
+4,449
+263% +$27K ﹤0.01% 5875
2024
Q1 		$12K Sell
1,689
-10,484
-86% -$79.5K ﹤0.01% 6137
2023
Q4 		$109K Buy
12,173
+7,220
+146% +$55.6K ﹤0.01% 5567
2023
Q3 		$47K Buy
4,953
+1,374
+38% +$17.8K ﹤0.01% 5817
2023
Q2 		$53K Buy
3,579
+2,989
+507% +$41.7K ﹤0.01% 5755
2023
Q1 		$7K Sell
590
-957
-62% -$15.6K ﹤0.01% 6463
2022
Q4 		$28K Buy
+1,547
New +$27.9K ﹤0.01% 6165

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Royal Bank of Canada's PRME Position: Q1 2026 in Review

Royal Bank of Canada increased its Prime Medicine (PRME) stake by 89% in Q1 2026, buying an estimated $16.6K and bringing the position to 9,254 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #5694.

Royal Bank of Canada first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $109K in Q4 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Royal Bank of Canada held 9,254 shares of Prime Medicine worth $32K as of Q1 2026.
  • Royal Bank of Canada bought 4,365 Prime Medicine shares in Q1 2026, an estimated $16.6K.
  • Prime Medicine made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5694 holding.
  • Royal Bank of Canada first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Royal Bank of Canada's Prime Medicine position peaked at $109K in Q4 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.